A new study reveals a surprising dual benefit for diabetics taking glucagon-like peptide 1 receptor agonists (GLP-1 agonists).
Beyond their role in regulating blood sugar levels, these injectables—popularly known for their off-label use as weight loss medications—emerge as formidable guardians against colorectal cancer.
